Refractory/Relapsed Autoimmune Hemolytic Anemia Clinical Trial
Official title:
A Phase II, Multicenter, Open-label Trial to Determine the Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic
This is an open-label, single-arm study to evaluate the safety and efficacy of Ibrutinib in subjects with refractory/relapsed autoimmune hemolytic anemia.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06021977 -
The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
|
Phase 2 |